Woodcock B G, Rietbrock N, Loh W, Habedank W D
Br J Clin Pharmacol. 1985 Dec;20(6):603-9. doi: 10.1111/j.1365-2125.1985.tb05118.x.
The absorption characteristics of dihydroergotoxine administered as an oral solution, tablet and retard capsule have been determined in a randomised cross-over investigation in 12 healthy males. The plasma concentrations of dihydroergotoxine produced by the three preparations, measured using a specific and sensitive radioimmuno-assay method over 24 h, exceeded 200 pg ml-1 for approximately 5 h and decayed in a biphasic manner with a slowest measured half-life of 12-14 h. The retard capsule differs from the other two preparations in having a low Cmax (50% of that recorded for the solution) and a clearly defined plateau. The bioavailability of the retard capsule was similar to that for the solution indicating that first-pass metabolism is not significantly increased following a three-fold prolongation in the absorption rate constant. The 20-40% greater bioavailability of dihydroergotoxine solution and retard capsule in comparison with the standard tablet may be due to a reduced contact time with gastric secretions achieved by means of rapid absorption from the stomach (solution) or delayed release at pH 1.5 (retard capsule).
在一项针对12名健康男性的随机交叉研究中,测定了口服溶液、片剂和缓释胶囊形式的双氢麦角毒碱的吸收特性。使用特定且灵敏的放射免疫分析法在24小时内测量三种制剂产生的双氢麦角毒碱血浆浓度,其在约5小时内超过200 pg/ml,并呈双相衰减,测得的最慢半衰期为12 - 14小时。缓释胶囊与其他两种制剂的不同之处在于其Cmax较低(为溶液记录值的50%)且有明确的平台期。缓释胶囊的生物利用度与溶液相似,表明吸收速率常数延长三倍后首过代谢未显著增加。与标准片剂相比,双氢麦角毒碱溶液和缓释胶囊的生物利用度高20 - 40%,这可能是由于通过从胃中快速吸收(溶液)或在pH 1.5时延迟释放(缓释胶囊)减少了与胃分泌物的接触时间。